1,176 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $185.6 $62.93B Buy
Article Searches
Revance completes pre-meeting with FDA, clinical trials on tap for H2; shares down 6% after hours http://seekingalpha.com/news/3193351-revance-completes-pre-meeting-fda-clinical-trials-tap-h2-shares-6-percent-hours?source=feed_news_all Jul 14, 2016 - Thinly traded micro cap Revance Therapeutics (RVNC) slumps 6% after hours on higher-than-average volume in apparent response to its announcement that it co
Allergan's Teva Update: Relax http://seekingalpha.com/article/3988443-allergans-teva-update-relax?source=feed_sector_healthcare Jul 14, 2016 - Allergan's sale of its generic business to Teva is proceeding.Closing the Teva transaction should be a major catalyst for Allergan shares.Capital allocation plan balances M&A flexibility, debt pay dow
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain http://www.zacks.com/stock/news/223394/teva-teva-provides-2016-2019-outlook-shares-gain?cid=CS-ZC-FT-223394 Jul 14, 2016 - Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
Teva to raise billions in bond sale next week http://seekingalpha.com/news/3193153-teva-raise-billions-bond-sale-next-week?source=feed_news_all Jul 14, 2016 - Teva Pharmaceutical (TEVA) will raise between $20B-$25B next week to finance its acquisition of Allergan's (AGN) generics business, Globes reports. The bon
Ruane Cunniff Comments on Allergan http://www.gurufocus.com/news/428389/ruane-cunniff-comments-on-allergan Jul 13, 2016 - Ruane Cunniff Comments on Allergan, Stocks: AGN, Ruane Cunniff, release date:Jul 13, 2016
Sequoia Fund Addresses Valeant, New Buys, Board Changes in —nd Quarter Letter http://www.gurufocus.com/news/428383/sequoia-fund-addresses-valeant-new-buys-board-changes-in-2nd-quarter-letter Jul 13, 2016 - Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter, Stocks: VRX,IDXX,AGN,CAB,KMX,CMG,SCHW,, Ruane Cunniff, release date:Jul 13, 2016
Why are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today? http://www.zacks.com/stock/news/223342/why-are-allergan-agn-and-teva-pharma-teva-stocks-up-today?cid=CS-ZC-FT-223342 Jul 13, 2016 - On Wednesday, shares of Allergan (AGN) and Teva Pharmaceuticals (TEVA) are both on the rise, up around 2% and 3%, respectively, in morning trading after Teva CEO Erez Vigodman said it expects its $40.5 billion acquisition of Allergan's generics business to close any day.
Who Splashed The Cash At The Top Of The Market? http://seekingalpha.com/article/3988138-splashed-cash-top-market?source=feed_all_articles Jul 13, 2016 - Those on the acquisition trail last year benefited from a slight dip in average deal values, an EP Vantage analysis shows, as rocky equity markets knocked valuations from their 2014 peak. Data collate
Teva bullish on synergies of Allergan deal, sees annual EBITDA growth of 14% through 2019; shares up 3% premarket http://seekingalpha.com/news/3192964-teva-bullish-synergies-allergan-deal-sees-annual-ebitda-growth-14-percent-2019-shares-3?source=feed_news_all Jul 13, 2016 - Teva's (TEVA) corporate presentation this morning has perked up investors. Shares are up 3% premarket on robust volume. CEO Erez Vigodman said that there a
Teva Raises Q2 Guidance; to Unveil 2016-2019 View http://www.zacks.com/stock/news/223261/teva-raises-q2-guidance-to-unveil-2016-2019-view?cid=CS-ZC-FT-223261 Jul 13, 2016 - Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.

Pages: 1...8788899091929394959697...118

<<<Page 92>